The Microclot Scandal: What the System Won't Test For, Won't Treat, Won't Even Acknowledge

The Microclot Scandal: What the System Won't Test For, Won't Treat, Won't Even Acknowledge

99 out of 99 cardiac patients had microclots, the clinical term for silent vessel buildup, circulating in their blood. The standard cardiac toolkit your doctor was handed doesn't test for it. Doesn't treat it. Doesn't even acknowledge it. Today, we're changing that.

The Scandal

About 700,000 Americans died of cardiovascular disease last year.

If American cardiovascular mortality were running at Japan's rate, roughly 350,000 fewer Americans would have died. Same wealth. Same hospital infrastructure. Half the death rate.

The cardiologists who built that lower floor have known about this silent buildup for forty-six years. American cardiology still doesn't put it on a lab requisition form.

Microclots, as the clinical literature calls them, are tiny, sticky knots of fibrin: the protein your body uses to seal a wound. In simpler terms, silent vessel buildup.

Normally, that protein gets broken down and cleared once the wound has healed. In millions of Americans, it doesn't:

1. It stays.
2. It accumulates.
3. It tangles into microscopic clusters and floats through the body's smallest blood vessels, too small to see on a scan, too small to feel, big enough to clog.

A 2022 peer-reviewed study tested 99 cardiac patients for this kind of fibrin accumulation. They found it in all 99 (Pretorius et al., Cardiovascular Diabetology, 2022).

The standard cardiac toolkit doesn't test for them.It doesn't treat them.It doesn't even acknowledge them.

Your doctor isn't the problem. The toolkit they were handed is. The American cardiovascular drug-and-procedure economy clears $400 billion a year. Patients with clean vessels don't move that number. So nothing in the standard kit addresses what is already built up inside your arteries.

This is not a failure of medicine. It is a failure of incentive.

The Science Is Settled. The System Isn't.

Picture the smallest blood vessels in your body. The capillaries running through your heart, your brain, your kidneys, your fingertips. They are narrower than a single red blood cell, which has to bend single-file to get through.

Now picture a knot of sticky fibrin (the protein your body uses to seal a wound, accumulating where it should not) the size of three red blood cells, slowly building up in those same vessels. The clinical literature calls it a microclot. In your body, it does not announce itself. It just gets stuck. Then another one gets stuck behind it. Then a third. The cells downstream stop getting fed. The tissue downstream starts to fail, quietly, organ by organ, year by year.

By the time it shows up on a scan, the damage has been compounding for a decade.

The science is not ambiguous. The treatment gap is.

More than 80 million Americans are on at least one standard cardiac drug. Roughly 40 million on a statin. 30 million on a daily antiplatelet like low-dose aspirin. 7 million on a long-term blood thinner. Not one of those drugs addresses the silent vessel buildup already accumulated in their arteries.

Mechanism by mechanism:

• Statins lower the cholesterol that forms new plaque (the cholesterol-and-cell buildup that hardens artery walls). They don't address plaque already there.
  • A 2022 trial in Frontiers in Cardiovascular Medicine followed 1,062 patients taking nattokinase for 12 months. The published outcomes included measurable reductions in carotid plaque size and artery-wall thickness (Chen et al., 2022).
• Blood thinners prevent new clots from forming. They don't break down the fibrin already accumulated in your vessels.
• Antiplatelets stop platelets from clumping. They don't touch the fibrin mesh holding existing buildup together.

Every approved drug in the cardiac category is built around prevention. None is built around clearance of what has already accumulated.

Why? Because the molecules that do break down fibrin in the body are natural enzymes. No patent. No trial funding. The industry doesn't invest in what it can't own.

Citations: Pretorius et al., Cardiovascular Diabetology, 2022. Chen et al., Frontiers in Cardiovascular Medicine, 2022. Nissen et al., ASTEROID, JAMA, 2006.

Introducing the Black Forest 4-in-1 Nattokinase 10,800 FU Complex

Today we introduce the most advanced 4-stage enzyme stack we have ever built: the Black Forest 4-in-1 Nattokinase 10,800 FU Complex.

Four clinically-dosed enzymes:

1. Nattokinase 10,800 FU
2. Serrapeptase 180,000 SPU
3. Lumbrokinase 40 mg
4. Vitamin K2 MK-7 180 mcg

in one enteric-coated, soy-free capsule. One daily with your largest meal.

We built it because no one else would.

What Is Nattokinase 10,800 FU?

Nattokinase is an enzyme isolated from nattō, the traditional Japanese fermented soybean dish, in 1980. It was the first dietary enzyme researched for activity on fibrin (the protein scaffold that builds up in vessels), studied for its support of the body's own clearing system.

Mechanism

Nattokinase is researched for its activity on fibrin and is studied for its support of the body's natural fibrin-clearing pathway.

What the research shows

• 36.6% reduction in carotid plaque size and 21.7% reduction in artery-wall thickness over 12 months in a 1,062-patient trial (Chen et al., Frontiers in Cardiovascular Medicine, 2022).
• ~5.5 mmHg systolic blood pressure reduction in mild hypertensives over 8 weeks at 2,000 FU/day (Kim et al., Hypertension Research, 2008).
• Measurable reduction in blood viscosity within hours of an oral dose in healthy adults (Hsia et al., Nutrition Research, 2009).

Why 10,800 FU

Most nattokinase on the shelf clocks in at 2,000 FU per capsule, the bare minimum to print the word on a label. 10,800 FU per capsule is more than five times the typical drugstore dose, at the high end of clinically studied dosing.

Why Soy-Free

Ours is fermented on a soy-free Bacillus subtilis substrate (rare in nattokinase). Matters for soy sensitivity, autoimmune concerns, or a soy-free preference.

Why Enteric-Coated

The coating gets the enzyme past stomach acid into the small intestine intact.

What Is Serrapeptase 180,000 SPU?

Serrapeptase was isolated from the gut of the silkworm, the same enzyme the moth uses to dissolve its cocoon and emerge.

Mechanism

Serrapeptase is a protein-digesting enzyme. It digests fibrin and the leftover protein debris and dead-cell fragments that nattokinase leaves behind.

What the research shows

• ~70% improvement in post-surgical inflammation and pain in early controlled trials (Tachibana et al., 1984; replicated in later otorhinolaryngology studies).
• Reduced sputum and mucus viscosity in respiratory inflammation conditions (Nakamura et al., Respirology, 2003).
• CRP (C-reactive protein) and inflammation marker reduction documented across the enzyme-therapy literature (Bhagat et al., 2013 review).

Why Pair It With Nattokinase

Nattokinase supports clearance of the fibrin mesh. Serrapeptase supports clearance of the debris. Without it, lingering debris re-triggers fresh fibrin accumulation downstream.

Why 180,000 SPU

SPU stands for Serrapeptase Units. Clinical thresholds for whole-body activity start around 40,000 SPU. At 180,000, the dose is built for full whole-body support, not just localized inflammation.

What Is Lumbrokinase 40 mg?

Lumbrokinase is an earthworm-derived enzyme used in traditional Asian medicine for centuries.

Mechanism

Where nattokinase handles fresh fibrin, lumbrokinase is researched for aged fibrin: the hardened, knotted buildup that has been accumulating for months or even years and resists nattokinase entirely.

What the research shows

• ~30% reduction in plasma fibrinogen levels in chronic cardiovascular subjects (multiple Chinese trials summarized in Cao et al., BMC Complementary & Alternative Medicine, 2013).
• Improvements in blood viscosity and platelet aggregation markers documented across the trials in the Cao 2013 systematic review.
• Direct fibrinolytic activity on aged fibrin material in animal and laboratory models (Mihara et al., 1991; replicated in Wang et al., 2019 pharmacology review).

Why It Matters Here

Adults with years of silent vessel buildup don't just need help slowing new accumulation. They need an enzyme that can support breakdown of what has already aged in the vessels. Lumbrokinase is the only oral enzyme research has shown to do that. It is also the enzyme most other formulas leave out, because it is expensive, hard to source, and hard to verify.

What Is Vitamin K2 (MK-7) 180 mcg?

Calcium ends up where you don't want it if you don't tell it where to go.

Mechanism

Vitamin K2 (MK-7) activates the protein that routes calcium away from artery walls toward bones, where it belongs. Arterial calcification (the calcium buildup that hardens artery walls) traps fibrin and accelerates artery decline. Supporting breakdown of the fibrin mesh without addressing the calcium leaves vessels still vulnerable. K2 closes that loop.

What the research shows

• ~50% lower arterial calcification scores in adults with the highest K2 intake versus the lowest (Rotterdam Study, Geleijnse et al., 2004).
• Arterial stiffening progression reversed at 180 mcg MK-7 daily over 3 years in a postmenopausal randomized trial. Placebo group stiffened; MK-7 group regressed (Knapen et al., Thrombosis & Haemostasis, 2015).

Why MK-7, Not MK-4

MK-7's half-life is 72 hours; MK-4's is one hour. One daily MK-7 dose covers a full day.

Why 180 mcg

180 mcg is the dose used in the Knapen MK-7 arterial-stiffness trial, at the upper end of clinical dosing.

What Happens When You Take One Capsule

You swallow it with your largest meal. The enteric coating gets the four enzymes past your stomach acid and into your small intestine, where they're absorbed into your bloodstream over the next 60 to 90 minutes.

Then they go to work in sequence.

First, nattokinase reaches the fresh fibrin buildup. Wherever the most recent fibrin scaffolding is accumulating, even a small patch you didn't know was forming, nattokinase is researched for its activity on it. Like fraying a fishing net into rope, then into thread, then into nothing.

Then serrapeptase supports cleanup of what nattokinase leaves behind. Broken fibrin still triggers inflammation. Inflammation tells your body to lay down more fibrin. Serrapeptase supports digestion of the debris so the inflammation signal can quiet. Cleanup crew, not breaking crew.

Then lumbrokinase reaches what nattokinase can't. The old, hardened, knotted fibrin buildup that has been accumulating for months or years. Nattokinase bounces off it. Lumbrokinase is researched for its activity on aged fibrin material, the kind that has aged past the point where nattokinase still acts.

And K2 routes the freed calcium to your bones. As old fibrin is broken down, the calcium that hardened around it is released. If that calcium ends up back in your artery walls, you have traded one problem for another. K2 activates the protein that directs that freed calcium to bone, where calcium belongs.

Four enzymes. Four jobs. One sequence. Take any one of them out and the sequence breaks. That is why this combination, in this order, at these doses.

Engineered around the way fibrin actually accumulates in the body: fresh, inflamed, aged, and trapped.

What's in the Bottle, and How We Tested It

Build, Materials & Verification:

• 60 capsules per bottle. 2-month supply at one daily.
• Enteric-coated for full delivery past stomach acid.
• Soy-free, independently verified per batch (rare in nattokinase).
• GMP-certified facility · Non-GMO · Made in USA.
• Vegan capsule shell (lumbrokinase, the earthworm enzyme, is delivered in a plant-based capsule).
• Third-party tested per batch: FU, SPU, mg, mcg. Lot-level Certificate of Analysis free on request, every order.

The Black Forest Guarantee

What is on the label is what is in the bottle. Lot-level Certificate of Analysis on request. 60-day full refund if the molecule does not agree with you. No return required.

The Mission

Conventional cardiology had 46 years to build a tool that clears what's already in your blood. They didn't.

So we did.

It is the first 4-stage enzyme stack at this dose ever assembled. And we built it for your heart.

The silent vessel buildup the standard cardiac toolkit doesn't address is what this stack was designed for. One capsule a day. Every day. For life.

The 80 million Americans on the standard cardiac drug toolkit won't read this. Their doctors won't tell them. Their insurance won't cover it.

You read this. Your body isn't going to do it alone.

Be the First

The first production run is limited.

We built it to clinical-grade standards: lab-verified per batch, Certificate of Analysis available on request, no shortcuts. The lumbrokinase alone, the enzyme every other formula leaves out, is expensive, hard to source, and hard to verify. We are not making this in volumes our existing supply chain can run on thin margin.

There are not many bottles in the first run.

Founding-batch pricing locks for 48 hours before public sale opens.

Be the First to Try the 4-in-1 Nattokinase Complex →

Clear your blood. Reclaim your heart.

Antonio Colmenares

CEO, Black Forest Supplements